Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial ...

Fintel reports that on February 12, 2025, Morgan Stanley downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from ...

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...

Third Harmonic Bio shares dived 35% in premarket trading amid a broader evaluation of THB335. Shares were trading around $3.03. The stock is down 50% over the last year.

Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform.Maximize Your Portfolio with Data Driven Insights:Leverage ...

American biotech Third Harmonic Bio and Inventiva have announced plans to reduce their respective workforces by 50% as part of cost-cutting measures. Both companies are shifting their focus to a ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

The full results of the Phase 1 trial will be presented at the AAAAI/WAO Joint Congress on Sunday, March 2, 2025. Meanwhile, Third Harmonic Bio plans to proceed with THB335 development activities ...

D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.